# A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

> **NCT02255513** · PHASE3 · COMPLETED · sponsor: **Ironshore Pharmaceuticals and Development, Inc** · enrollment: 43 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** HLD200
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02255513
- **Lead sponsor:** Ironshore Pharmaceuticals and Development, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255513, "A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02255513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*